{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:20:41Z","timestamp":1777706441898,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P42 ES027704"],"award-info":[{"award-number":["P42 ES027704"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["F32 ES026005"],"award-info":[{"award-number":["F32 ES026005"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007904","name":"Texas A and M University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000139","name":"U.S. Environmental Protection Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.taap.2020.115069","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:18:36Z","timestamp":1590009516000},"page":"115069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice"],"prefix":"10.1016","volume":"400","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0879-3098","authenticated-orcid":false,"given":"Chimeddulam","family":"Dalaijamts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Cichocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Syuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9340-7384","authenticated-orcid":false,"given":"Ivan","family":"Rusyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihsueh A.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2020.115069_bb0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2012.05.019","article-title":"Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis","volume":"57","author":"Abdelmegeed","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.taap.2020.115069_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.apha.2019.01.003","article-title":"Drug-induced liver injury in obesity and nonalcoholic fatty liver disease","volume":"85","author":"Allard","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.redox.2017.06.008","article-title":"Non-alcoholic fatty liver disease, to struggle with the strangle: oxygen availability in fatty livers","volume":"13","author":"Anavi","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.taap.2020.115069_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1020281327116","article-title":"An introduction to MCMC for machine learning","volume":"50","author":"Andrieu","year":"2003","journal-title":"Machine Learning"},{"key":"10.1016\/j.taap.2020.115069_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1148\/radiol.13132294","article-title":"Science to practice: can we diagnose nonalcoholic steatohepatitis with Intravoxel incoherent motion diffusion-weighted MR imaging?","volume":"270","author":"Beers","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/j.taap.2020.115069_bb0030","doi-asserted-by":"crossref","first-page":"E939","DOI":"10.1152\/ajpendo.00379.2007","article-title":"Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice","volume":"294","author":"Begriche","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2020.115069_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1289\/ehp.00108s2275","article-title":"Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics","volume":"108","author":"Bois","year":"2000","journal-title":"Environmental health perspectives"},{"issue":"Suppl. 2","key":"10.1016\/j.taap.2020.115069_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1289\/ehp.00108s2307","article-title":"Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics","volume":"108","author":"Bois","year":"2000","journal-title":"Environmental health perspectives"},{"key":"10.1016\/j.taap.2020.115069_bb0045","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/bioinformatics\/btp162","article-title":"GNU MCSim: Bayesian statistical inference for SBML-coded systems biology models","volume":"25","author":"Bois","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.taap.2020.115069_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-7843.2009.00488.x","article-title":"Physiologically based modelling and prediction of drug interactions","volume":"106","author":"Bois","year":"2010","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"10.1016\/j.taap.2020.115069_bb0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0300-483X(90)90195-M","article-title":"Liver tumor induction in B6C3F1 mice by dichloroacetate and trichloroacetate","volume":"63","author":"Bull","year":"1990","journal-title":"Toxicology"},{"key":"10.1016\/j.taap.2020.115069_bb0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.etap.2004.12.026","article-title":"Developing an exposure\u2013dose\u2013response model for the acute neurotoxicity of organic solvents: overview and progress on in vitro models and dosimetry","volume":"19","author":"Bushnell","year":"2005","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2003.50095","article-title":"Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis","volume":"37","author":"Chalasani","year":"2003","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.taap.2020.115069_bb0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.taap.2011.03.020","article-title":"Development and evaluation of a harmonized physiologically based pharmacokinetic (PBPK) model for perchloroethylene toxicokinetics in mice, rats, and humans","volume":"253","author":"Chiu","year":"2011","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00335-017-9731-6","article-title":"Advancing chemical risk assessment decision-making with population variability data: challenges and opportunities","volume":"29","author":"Chiu","year":"2018","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.taap.2020.115069_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.taap.2009.07.032","article-title":"Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach","volume":"241","author":"Chiu","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1289\/ehp.1307623","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of Interstrain variability in trichloroethylene metabolism in the mouse","volume":"122","author":"Chiu","year":"2014","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.taap.2020.115069_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.116.232629","article-title":"Target organ metabolism, toxicity, and mechanisms of trichloroethylene and Perchloroethylene: key similarities, differences, and data gaps","volume":"359","author":"Cichocki","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2020.115069_bb0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.116.238790","article-title":"Impact of nonalcoholic fatty liver disease on Toxicokinetics of tetrachloroethylene in mice","volume":"361","author":"Cichocki","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2020.115069_bb0105","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/toxsci\/kfx120","article-title":"Nonalcoholic fatty liver disease is a susceptibility factor for Perchloroethylene-induced liver effects in mice","volume":"159","author":"Cichocki","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2020.115069_bb0110","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/toxsci\/kfy223","article-title":"Modulation of tetrachloroethylene-associated kidney effects by nonalcoholic fatty liver or steatohepatitis in male C57BL\/6J mice","volume":"167","author":"Cichocki","year":"2019","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.taap.2020.115069_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.taap.2020.115069_bb0120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.4254\/wjh.v6.i7.496","article-title":"CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"6","author":"Cocciolillo","year":"2014","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.taap.2020.115069_bb0125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/10408440802209796","article-title":"Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites","volume":"38","author":"Corton","year":"2008","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.taap.2020.115069_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-015-9293-x","article-title":"Three common pathways of nephrotoxicity induced by halogenated alkenes","volume":"31","author":"Cristofori","year":"2015","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.taap.2020.115069_bb0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.taap.2018.05.033","article-title":"Incorporation of the glutathione conjugation pathway in an updated physiologically-based pharmacokinetic model for perchloroethylene in mice","volume":"352","author":"Dalaijamts","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2020.115069_bb0145","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1124\/jpet.107.120444","article-title":"S-(1,2,2-trichlorovinyl)-L-cysteine sulfoxide, a reactive metabolite of S-(1,2,2-Trichlorovinyl)-L-cysteine formed in rat liver and kidney microsomes, is a potent nephrotoxicant","volume":"321","author":"Elfarra","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2020.115069_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1620\/tjem.215.89","article-title":"Portal vein hemodynamics in patients with non-alcoholic fatty liver disease","volume":"215","author":"Erdogmus","year":"2008","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.taap.2020.115069_bb0155","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ar.20715","article-title":"Hepatic microcirculation in fatty liver disease","volume":"291","author":"Farrell","year":"2008","journal-title":"Anat. Rec."},{"key":"10.1016\/j.taap.2020.115069_bb0160","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2020.115069_bb0165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/01621459.1990.10476213","article-title":"Sampling-based approaches to calculating marginal densities","volume":"85","author":"Gelfand","year":"1990","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.taap.2020.115069_bb0170","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1080\/01621459.1996.10476708","article-title":"Physiological pharmacokinetic analysis using population modeling and informative prior distributions","volume":"91","author":"Gelman","year":"1996","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.taap.2020.115069_bb0175","series-title":"Bayesian Data Analysis","author":"Gelman","year":"2004"},{"key":"10.1016\/j.taap.2020.115069_bb0180","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1109\/TPAMI.1984.4767596","article-title":"Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images","volume":"PAMI-6","author":"Geman","year":"1984","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"10.1016\/j.taap.2020.115069_bb0185","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1148\/radiol.12112478","article-title":"Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study","volume":"265","author":"Guiu","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.taap.2020.115069_bb0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1289\/ehp.1307359","article-title":"Human health effects of tetrachloroethylene: key findings and scientific issues","volume":"122","author":"Guyton","year":"2014","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.taap.2020.115069_bb0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/rtph.2001.1517","article-title":"Genetic polymorphisms in assessing interindividual variability in delivered dose","volume":"35","author":"Haber","year":"2002","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tox.2005.12.017","article-title":"Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models","volume":"221","author":"Hack","year":"2006","journal-title":"Toxicology"},{"key":"10.1016\/j.taap.2020.115069_bb0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yrtph.2006.05.012","article-title":"Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites","volume":"46","author":"Hack","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0210","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10928-016-9492-y","article-title":"Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine","volume":"43","author":"Hartmanshenn","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.taap.2020.115069_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.reprotox.2016.10.001","article-title":"Metabolism disrupting chemicals and metabolic disorders","volume":"68","author":"Heindel","year":"2017","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.taap.2020.115069_bb0220","series-title":"IARC monographs on the evaluation of carcinogenic risks to humans: trichloroethylene, tetrachloroethylene and some other chlorinated agents (Vol. 106)","author":"IARC","year":"2014"},{"key":"10.1016\/j.taap.2020.115069_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2193-9616-1-9","article-title":"The simcyp population based simulator: architecture, implementation, and quality assurance","volume":"1","author":"Jamei","year":"2013","journal-title":"In Silico Pharmacol"},{"key":"10.1016\/j.taap.2020.115069_bb0230","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.taap.2020.115069_bb0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.taap.2020.115069_bb0240","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2193-9616-1-6","article-title":"Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification","volume":"1","author":"Krauss","year":"2013","journal-title":"In Silico Pharmacology"},{"key":"10.1016\/j.taap.2020.115069_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0031-6997(24)01491-1","article-title":"Hepatic and renal toxicities associated with Perchloroethylene","volume":"53","author":"Lash","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.taap.2020.115069_bb0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mrrev.2014.04.003","article-title":"Trichloroethylene biotransformation and its role in mutagenicity, Carcinogenicity and Target Organ Toxicity, Mutation Research","volume":"762","author":"Lash","year":"2014","journal-title":"Reviews in mutation research"},{"key":"10.1016\/j.taap.2020.115069_bb0260","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/psp4.39","article-title":"A mechanistic pharmacokinetic model for liver transporter substrates under liver cirrhosis conditions","volume":"4","author":"Li","year":"2015","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.taap.2020.115069_bb0265","series-title":"Using Collaborative Cross Mouse Population to Fill Data Gaps in Risk Assessment: A Case Study of Population-Based Analysis of Toxicokinetics and Kidney Toxicodynamics of Tetrachloroethylene. Environmental health perspectives","first-page":"127","author":"Luo","year":"2019"},{"key":"10.1016\/j.taap.2020.115069_bb0270","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/toxsci\/kfy099","article-title":"Metabolism and toxicity of trichloroethylene and tetrachloroethylene in cytochrome P450 2E1 knockout and humanized transgenic mice","volume":"164","author":"Luo","year":"2018","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2020.115069_bb0275","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.xphs.2017.04.035","article-title":"Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine","volume":"106","author":"Marsousi","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2020.115069_bb0280","series-title":"(National Research Council) Review of the Environmental Protection Agency's Draft IRIS Assessment of Tetrachloroethylene","author":"NRC","year":"2010"},{"key":"10.1016\/j.taap.2020.115069_bb0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.hepres.2005.10.001","article-title":"Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients","volume":"34","author":"Orellana","year":"2006","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.taap.2020.115069_bb0290","first-page":"1295","article-title":"Non-alcoholic fatty liver disease\u2013clinical and histopathological aspects","volume":"57","author":"Popescu","year":"2016","journal-title":"Romanian J. Morphol. Embryol."},{"key":"10.1016\/j.taap.2020.115069_bb0295","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3758\/s13423-016-1015-8","article-title":"A simple introduction to Markov chain Monte-Carlo sampling","volume":"25","author":"van Ravenzwaaij","year":"2018","journal-title":"Psychon. Bull. Rev."},{"key":"10.1016\/j.taap.2020.115069_bb0300","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2217\/pgs.10.100","article-title":"Toxicogenetics: population-based testing of drug and chemical safety in mouse models","volume":"11","author":"Rusyn","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.taap.2020.115069_bb0305","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00535-012-0581-4","article-title":"Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?","volume":"47","author":"Shigefuku","year":"2012","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.taap.2020.115069_bb0310","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3727\/105221617X15093707969658","article-title":"Updates on dietary models of nonalcoholic fatty liver disease: current studies and insights","volume":"18","author":"Stephenson","year":"2018","journal-title":"Gene Expr."},{"key":"10.1016\/j.taap.2020.115069_bb0315","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/dmd.110.037838","article-title":"A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions","volume":"39","author":"Strougo","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2020.115069_bb0320","series-title":"Toxicological review of tetrachloroethylene (CAS no. 127-18-4) in support of summary information on the integrated risk information system (IRIS)","author":"USEPA","year":"2011"},{"key":"10.1016\/j.taap.2020.115069_bb0325","series-title":"Toxicological review of trichloroethylene (CAS no. 79-01-6) in support of summary information on the integrated risk information system (IRIS)","author":"USEPA","year":"2011"},{"key":"10.1016\/j.taap.2020.115069_bb0330","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s00535-016-1298-6","article-title":"Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH)","volume":"52","author":"Utsunomiya","year":"2017","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.taap.2020.115069_bb0335","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11901-014-0225-7","article-title":"NAFLD and hepatocellular carcinoma: how big a problem is this really?","volume":"13","author":"Vanni","year":"2014","journal-title":"Current Hepatology Reports"},{"key":"10.1016\/j.taap.2020.115069_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.taap.2020.115069_bb0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1289\/ehp.1205687","article-title":"Addressing human variability in next-generation human health risk assessments of environmental chemicals","volume":"121","author":"Zeise","year":"2013","journal-title":"Environ. Health Perspect."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X20301939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:46:50Z","timestamp":1777456010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X20301939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":67,"alternative-id":["S0041008X20301939"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2020.115069","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2020.115069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115069"}}